Clinical usefulness of positron emission tomography - Computed tomography in recurrent thyroid carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 2, 2010, Pages 120-125

  Razfar, Ali ^a   Branstetter IV, Barton F ^a,b   Christopoulos, Apostolos ^a   Lebeau, Shane O ^a   Hodak, Steven P ^a   Heron, Dwight E ^c   Escott, Edward J ^b   Ferris, Robert L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY HEALTH CARE; THYROID CARCINOMA; TREATMENT PLANNING;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADENOMA, OXYPHILIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77149135765     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.215     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83(12):2638-2648.
4. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology. 1999;13 (suppl 11A):391-442.
5. Spencer CA, Wang CC. Thyroglobulin measurement: techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am. 1995;24(4):841-863.
6. 131I scan. J Nucl Med. 2001;42(1):71-76.
7. Al-Nahhas AM. FDG PET and alternative imaging in the management of thyroid carcinoma. Nucl Med Rev Cent East Eur. 2003;6(2):139-145.
8. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26(12):1547-1552.
9. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84(7):2291-2302.
10. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498-505.
11. Branstetter BF IV, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235(2):580-586.
12. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32(9):690-695.
13. 131I-negative thyroid cancer. Ann Surg Oncol. 2008;15(1):286-292.
14. Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol. 2009;70(1):17-24.
15. Mirallié E, Guillan T, Bridji B, et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery. 2007;142(6):952-958.
16. Freudenberg LS, Frilling A, Kühl H, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol. 2007;17(12):3139-3147.
17. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer [published correction appears in J Nucl Med. 2007;48(3):412]. J Nucl Med. 2007;48(2):221-226.
18. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005;115(2):237-243.
19. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging. 2007;34(4):487-495.
20. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg. 2003;128(2):178-184.
21. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47(4):616-624.
22. Lin JD, Huang MJ, Hsu BR, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol. 2002;80(1):45-51.
23. Hamy A, Mirallié E, Bennouna J, et al. Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer. Eur J Surg Oncol. 2004;30(6):681-685.
24. Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36(3):753-778, vii.